vitro and in vivo synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains. Biological & Pharmaceutical
S; Middleton, M; Mazar, A; Harris, A. L. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clinical Cancer Research
rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillière's Clinical Endocrinology and Metabolism. 1998, 12 (3): 501–506